BioSpace News Archive

In time for the 2023 cotton planting season, Bollgard® 3 ThryvOn™ cotton with XtendFlex® Technology is now commercially available.

MetiStream Incorporated is expanding its relationship with Carilion Clinic, a Roanoke, VA-headquartered healthcare system, to identify high-risk colon cancer patients using MetiStream’s Artificial Intelligence enabled Ember Platform.

Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that it has been invited to present at the 2023 OBIO Investment Summit (OIS) in Toronto on Friday, February 10th at 11:51am EST.

Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023.

Optimi Health Corp. is pleased to announce the submission of its clinical trial application (CTA) for a Phase I combinatorial study that will document the safety of Optimi’s natural psilocybin standardized extract and proprietary 3,4-methylenedioxy-methamphetamine (MDMA) drug candidate in healthy therapist subjects.

OSSIO, Inc., a fast-growing orthopedic fixation technology company, announced the introduction of the new OSSIOfiber® Compression Staple, the next step towards becoming the gold standard in orthopedic fixation.

Onconova Therapeutics, Inc. today announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, February 16, 2023, at 4:30 p.m. Eastern Time (ET) to review its 2022 financial results and provide a business update.

BrickBio has overcome previous limitations in unnatural amino acid driven site-specific conjugation by achieving stable, mammalian cell lines 5x faster than previous leaders in the space with 7x enhanced production.

Edgewise Therapeutics, Inc. today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 pm ET.